Insider Transactions in Q4 2024 at Kiniksa Pharmaceuticals, Ltd. (KNSA)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 18
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
17,000
-14.17%
|
$357,000
$21.04 P/Share
|
|
Nov 18
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+7.69%
|
$10,000
$1.59 P/Share
|
|
Nov 07
2024
|
Richard S Levy |
BUY
Exercise of conversion of derivative security
|
Direct |
1,303
+8.4%
|
-
|
|
Nov 06
2024
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Open market or private sale
|
Direct |
89,561
-52.96%
|
$2,059,903
$23.0 P/Share
|
|
Nov 06
2024
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
89,561
+34.62%
|
$89,561
$1.59 P/Share
|
|
Oct 15
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
17,000
-13.39%
|
$442,000
$26.87 P/Share
|
|
Oct 15
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+7.3%
|
$10,000
$1.59 P/Share
|
|
Oct 04
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
82
-0.31%
|
$1,968
$24.48 P/Share
|
|
Oct 04
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
175
+0.65%
|
-
|
|
Oct 04
2024
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
9,460
+1.86%
|
-
|